Nature Reviews Drug Discovery

Nature Reviews Drug Discovery, Published online: 12 June 2026; doi:10.1038/d41573-026-00099-1 David Reese, Amgen’s inaugural Chief Technology Officer, discusses how inconspicuous AI achievements stand to transform drug discovery.

Nature Reviews Drug Discovery, Published online: 12 June 2026; doi:10.1038/d41573-026-00103-8 Upcoming FDA approval decisions in Q3 2026

Nature Reviews Drug Discovery, Published online: 12 June 2026; doi:10.1038/d41573-026-00102-9 Novel drug targets in 2025

Nature Reviews Drug Discovery, Published online: 11 June 2026; doi:10.1038/d41573-026-00100-x First CD123-targeted ADC secures FDA approval for rare blood cancer

Nature Reviews Drug Discovery, Published online: 11 June 2026; doi:10.1038/d41573-026-00101-w Antiviral peptide nabs FDA approval for hepatitis delta virus infection

Nature Reviews Drug Discovery, Published online: 10 June 2026; doi:10.1038/d41573-026-00098-2 Advancing ferroptosis-targeted therapies

Nature Reviews Drug Discovery, Published online: 10 June 2026; doi:10.1038/d41573-026-00097-3 Evolution of the psoriasis therapy landscape

Nature Reviews Drug Discovery, Published online: 09 June 2026; doi:10.1038/d41573-026-00082-w Analysis of a decade of post-authorisation studies for medicines approved by the EMA

Nature Reviews Drug Discovery, Published online: 09 June 2026; doi:10.1038/d41573-026-00096-4 Implantable hydrogel encapsulates ‘living therapeutics’

Nature Reviews Drug Discovery, Published online: 08 June 2026; doi:10.1038/s41573-026-01473-9 Reply to ‘Stimulating medicines repurposing in the EU: a pilot project’

Nature Reviews Drug Discovery, Published online: 08 June 2026; doi:10.1038/d41573-026-00095-5 ASO sustains microglial neural repair activity

Nature Reviews Drug Discovery, Published online: 04 June 2026; doi:10.1038/d41573-026-00094-6 The ongoing outbreak of Bundibugyo Ebola virus disease in the Democratic Republic of the Congo highlights the urgent need to bridge therapeutic gaps for non-Zaire ebolaviruses by prioritizing and accelerating development and evaluation of broadly applicable and species-specific filovirus countermeasures.

Nature Reviews Drug Discovery, Published online: 03 June 2026; doi:10.1038/s41573-026-01459-7 mRNA technology is being applied to develop a new generation of therapies for rare and common diseases. This Review discusses insights from clinical studies on mRNA-based therapeutics, including enzyme replacement therapies, cancer immunotherapies, genome-modifying therapies and immune cell reprogramming…

Nature Reviews Drug Discovery, Published online: 03 June 2026; doi:10.1038/d41573-026-00093-7 Informing HIV vaccine design

Nature Reviews Drug Discovery, Published online: 03 June 2026; doi:10.1038/d41573-026-00090-w Inhibiting lactate transport reduces lung fibrosis

Nature Reviews Drug Discovery, Published online: 03 June 2026; doi:10.1038/d41573-026-00091-9 Understanding Ras inhibitor resistance

Nature Reviews Drug Discovery, Published online: 03 June 2026; doi:10.1038/d41573-026-00092-8 Inhibiting Nipah virus

Nature Reviews Drug Discovery, Published online: 29 May 2026; doi:10.1038/d41573-026-00089-3 Despite transformative advances in adult oncology, children with cancer remain systematically underserved by drug development pipelines. We argue that sequential, siloed paediatric development is no longer defensible. Integrating paediatric considerations from drug discovery onwards, and leveraging tumour…

Nature Reviews Drug Discovery, Published online: 29 May 2026; doi:10.1038/d41573-026-00083-9 Over the last decade, progress in science and technology has not only spurred biomedical innovation but has also led to an exponential growth in healthcare and regulatory data. When such data are carefully managed, they can inform medicines developers and regulators to further improve decision making and …

Nature Reviews Drug Discovery, Published online: 28 May 2026; doi:10.1038/s41573-026-01450-2 Claudins are emerging as clinically actionable targets in cancer, exemplified by the approval of CLDN-18.2-directed therapy. This review examines the biological basis and therapeutic exploitation of claudins, highlighting diverse targeting modalities and the shift towards leveraging tight junction compone…